CFN Media Exclusive CEO Interview: InMed Pharmaceuticals'

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
46
CFN Media Exclusive CEO Interview: InMed Pharmaceuticals' Biosynthesis Platform Results in an Industry First

SEATTLE, WA--(Marketwired - Nov 6, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an exclusive video interview with Eric A. Adams, CEO of InMed Pharmaceuticals Inc. ( CSE : IN )( CSE : IN.CN )( CNSX : IN )( OTCQB : IMLFF ). In this interview, CEO Eric A. Adams talks about the company's recent breakthrough, a study in which the team was able to identify a cannabinoid drug candidate for the treatment of glaucoma; biosynthesize that cannabinoid; develop a proprietary hydrogel delivery system; and effectively apply the new drug to the eye in a positive preclinical study.

Cannabis Industry Challenges The cannabis industry is projected to reach $50 billion in size by 2026, according to Cowen & Co., driven by the legalization of recreational marijuana in states like California and Nevada. While many investors are focused on the recreational space, many companies have been advancing clinical trials demonstrating the medical value of cannabinoids in treating conditions like epilepsy, cancer pain, and glaucoma. Cannabinoids, the chemicals within the plant, are experiencing a significant interest in the research and development & commercialization of products for the pharmaceutical & nutraceutical markets. CBD, as an example, in the U.S alone, has been estimated to grow to a $3b market by 2012, according to GreenWave Advisors.

Despite the remarkable growth, the industry faces many challenges when it comes to developing cannabinoid therapeutics and products. The process of growing, harvesting, extracting, and purifying cannabinoids is extremely costly and time-consuming. Many cannabinoids are also only found in trace amounts, which makes extraction economically unfeasible. At the same time, chemical synthesis has its own set of challenges and laboratory costs.

The ideal solution would be an easily scalable way to produce all 90+ cannabinoids within the cannabis plant to realize the synergistic effects that they have on each other. In addition, the process should be scalable in a way that medications could be easily manufactured for millions of people without the environmental and economic costs of growing and harvesting full cannabis plants only to use a small portion of them.

Unique Biosynthesis Program InMed noticed that these problems mirrored a similar problem facing diabetics after the discovery of insulin. Prior to genetic advances in the 1970s, insulin was produced by manually extracting and purifying the drug from animals. Millions of people suffered from diabetes, but extraction from animals was an unsustainable and harmful way to mass-produce a drug that was required in perpetuity by each patient.

In 1979, researchers discovered that the bacterium E. coli could be genetically engineered to produce insulin without having to extract it from animals. The vast majority of insulin sold around the world is now biosynthetic recombinant "human" insulin or its analogues.

InMed set out to apply the same process to produce cannabinoids at scale. The company systematically introduced the cannabis plant's metabolic pathways into an E. coli-based manufacturing system and reported the production of downstream cannabinoids in these hosts. This could open the door to industrial-scale manufacturing of naturally-occurring cannabinoids and represents a big advancement over existing methods. This disruptive technology would be a game changer for the industry and a possible replacement for the current plant-based extraction methods.

In late-September, the company announced that it has successfully demonstrated that it can produce multiple "gateway" cannabinoids using genetically engineered microorganisms. These molecules can be functionalized further to produce any of the 90+ "downstream" cannabinoids found naturally in the cannabis plant. The company had employed this production chassis to synthesize compounds for pharmaceutical research programs.

Importantly, InMed announced that Ben Paterson has been retained for the development of this program. Mr. Paterson has nearly four decades of experience in developing pharmaceutical manufacturing and purification processes. He was previously a Senior Engineering Advisor with Eli Lilly and Company, where he spent 37 years, including 24 years in their biosynthesis division. His expertise includes first defining processes in the lab, then scaling up to pilot and commercial scale. Mr. Paterson has conducted design, construction, operation, optimization, and troubleshooting of both large and small molecule drug facilities including the E. coli biosynthesis of numerous products. He brings experience in the seamless integration of biochemistry, equipment, and process control to successfully define a "process" at scale.

Positive Early Clinical Results InMed's initial application of this technology has been in the ocular market where it recently announced positive pre-clinical data on its hydrogel cannabinoid product formulation. The study was the first ever to use a nanoparticle hydrogel for cannabinoid drug delivery into the eye, which resulted in direct drug uptake by the cornea and lens. The full results have been submitted to a peer-reviewed journal for publication.

Eye drops are the conventional delivery method for eye treatments, but they are easily washed away when blinking. On average, less than 5% of the drug reaches its target tissue. Hydrogel offers unique rheological characteristics that enable it to form a thin uniform coating, a 'gel-like lens,' over the cornea through the blinking of the eyelid. The lens holds in place and allows transcorneal absorption of the drug that was three times higher than the control formulation.

More importantly, the study showcases the company's capacity to complete various full-scale drug development programs using its biosynthesis process and other drug development technologies, including its bioinformatics platform. These same tools could be applied to other clinical programs or even licensed to pharmaceutical companies that wish to improve their drug development programs.

The company estimates that sometime in 2018 is very realistic for filing an IND and moving towards Phase 1 clinical trials.

Please follow the link to see the interview and read the full article: http://www.cannabisfn.com/inmed-pharmaceutica...try-first/

About CFN Media CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id...?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

Disclaimer: Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/

CFN Media Frank Lane 206-369-7050 flane@cannabisfn.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 109

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 109

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 97

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading

Top 5 Most Recently Viewed Articles

Ready Capital Corporation's 2024 Results Overview & Future Insights

Updated Category News Views 176

Ready Capital Corporation's Upcoming Financial Results Ready Capital Corporation (NASDAQ: RC) is poised to share its financial results for the fourth quarter and the full year of 2024. This significant announcement is expected to take place before the opening bell of the New York Stock Exchange on the designated release date. Investors and interested parties are eagerly...

Continue Reading
Nano-X Faces Securities Suit, Investors Alerted

Updated Category News Views 32

Legal Tsunami Hits Nano-X Imaging If there’s one thing that makes investors' hairs stand on end, it’s the words 'class action lawsuit.' And now, it's swirling around Nano-X Imaging Ltd. (NASDAQ: NNOX) like a tempest. The DJS Law Group has taken the lead, lighting the legal torches on claims that Nano-X fed investors a cocktail of misleading statements regarding its...

Continue Reading
Novo Nordisk A/S Shareholders: Take Action on Recent Allegations

Updated Category News Views 218

Understanding the Novo Nordisk A/S Class Action Opportunity Recent developments have led to significant scrutiny of Novo Nordisk A/S, a major player in the pharmaceutical industry. For shareholders, this highlights a crucial opportunity to engage in a class action lawsuit regarding alleged misleading statements about the company's CagriSema weight loss study results....

Continue Reading
Investors of Inspire Medical Systems Should Act Before Deadline

Updated Category News Views 288

Important Deadline for Inspire Medical Systems Investors Investors of Inspire Medical Systems, Inc. are reminded that a critical deadline is approaching for those who purchased securities. The firm Kirby McInerney LLP has encouraged investors to take action as they seek the lead plaintiff role in a federal securities class action. About the Legal Proceedings This lawsuit...

Continue Reading
Nicholas Wealth's Impressive $GIAX Distribution Yield Announcement

Updated Category News Views 88

Recent Announcement from Nicholas Wealth Management Nicholas Wealth, renowned for its commitment to delivering actively managed income ETFs, has made an exciting announcement regarding its latest distribution. The Nicholas Global Equity and Income ETF (GIAX) will offer investors a substantial monthly distribution yield of an impressive 24.00%. This announcement is...

Continue Reading